News Search Results
Apr 20, 2026, 08:30 ET Pinnacle Food Group Limited Announces Entry Into a Non-Binding MOU to Explore Establishing an Open Yeast Platform Hub in Hong Kong
established by Dr. Scott Pownall in 2021. The current library contains hundreds of valuable DNA assembly parts to support synthetic biology research and biotechnology in yeast. The second part is the Open Yeast Strain Bank, an open-access, growing library of yeast strains made available to researchers worldwide.
More news about: Pinnacle Food Group Limited
Apr 20, 2026, 08:00 ET Deck Bio Presents Preclinical Data on DBXO-1, a Multi-pMHC Targeted T Cell Engager, at AACR 2026
Deck Bio, a biotechnology company advancing multi-pMHC targeted T cell engagers for solid tumors, today presented new preclinical data for its lead program, DBXO-1, at the
More news about: Deck Bio, Inc.
Apr 20, 2026, 08:00 ET Sapience Therapeutics Presents First Clinical Results from Phase 2 Study of ST316, First-in-Class β-catenin Antagonist, in Second-Line Colorectal Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2026
TARRYTOWN, N.Y., April 20, 2026 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today
More news about: Sapience Therapeutics, Inc.
Apr 20, 2026, 08:00 ET Argo Biopharma Doses First Patients in Phase II Clinical Trials of siRNA Therapy BW-40202
effectively slow disease progression and improve long-term outcomes.About Argo BiopharmaArgo Biopharma is a clinical-stage biotechnology company committed to developing next-generation RNAi therapeutics to provide better treatment options for patients worldwide. The company has established
More news about: Argo Biopharmaceutical Co., Ltd
Apr 20, 2026, 08:00 ET Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates
vision to deliver new treatments to cancer patients with limited options."About Adcendo ApSAdcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts. The company is developing a pipeline of first- and potential
More news about: Adcendo
Apr 20, 2026, 08:00 ET Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates
vision to deliver new treatments to cancer patients with limited options."About Adcendo ApSAdcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts. The company is developing a pipeline of first- and potential
More news about: Adcendo
Apr 20, 2026, 07:30 ET 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin
SAN FRANCISCO, April 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced new results from a blinded 16-week treatment extension period in its
More news about: Nektar Therapeutics
Apr 20, 2026, 07:30 ET TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
regulatory authority, and its safety and effectiveness have not been established.About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities.
More news about: TJ Biopharma
Apr 20, 2026, 03:00 ET Middlesex Community College and Empowered Hosted by Meg Ryan Examine Pathways to Economic Mobility and Workforce Success
students at their current stage of life, whether they are recent high school graduates or adult learners seeking to pivot into new sectors such as biotechnology or advanced manufacturing. Beyond technical proficiency, the documentary emphasizes the mentorship and holistic support services that ensure students
More news about: Empowered with Meg Ryan
Apr 19, 2026, 12:00 ET Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026
SAN FRANCISCO, April 19, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review 52-week topline
More news about: Nektar Therapeutics
Apr 18, 2026, 19:35 ET Breakthrough Prize Foundation Announces Winner of the 11th Annual Breakthrough Junior Challenge
discovery, and innovation to make lives better. CSHL's DNA Learning Center (DNALC) is the largest provider of hands-on instruction in genetics and biotechnology, reaching nearly 40,000 middle and high school students through field trips, day camps, summer camps, mentored research projects, and teacher training.
More news about: Breakthrough Prize
Apr 17, 2026, 16:01 ET Kalohexis Announces Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
NORTHBROOK, Ill., April 17, 2026 /PRNewswire/ -- Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced
More news about: Kalohexis
Apr 17, 2026, 15:00 ET Nested Therapeutics Reports Initial Encouraging Clinical Activity and Favorable Tolerability of NST-628, a Brain-Penetrant Pan-RAF/MEK Molecular Glue, at AACR 2026
durable pathway suppression across RAS/MAPK-driven cancers.About Nested TherapeuticsNested Therapeutics is a clinical-stage biotechnology company dedicated to developing transformative therapies for RAS/MAPK-driven disorders. The company is advancing NST-628, a fully brain-penetrant,
More news about: Nested Therapeutics Inc.
Apr 17, 2026, 11:00 ET CREATE Medicines to Showcase Multi-immune In Vivo CAR T, CAR NK, and All-RNA RetroT Platform at AACR 2026
CAMBRIDGE, Mass., April 17, 2026 /PRNewswire/ -- CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune cell programming, today announced it will present two posters at the American Association for Cancer Research
More news about: CREATE Medicines, Inc.
Apr 17, 2026, 09:18 ET Precision Biologics to Reveal New AML Target for CAR-NK at American Association for Cancer Research (AACR) Annual Meeting on April 19th, 2026
with over 11,000 deaths. (seer.cancer.gov)About Precision BiologicsFounded in 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic and diagnostic products for the detection and treatment of cancer. The company's antibody drug candidates
More news about: Precision Biologics
Apr 17, 2026, 08:30 ET Marengo Reports Late-Breaking Initial Phase 2 Clinical Results from Invikafusp Alfa Plus TRODELVY® and Unveils Partnered Novel IPN01203/STAR0501 STAR Program in Phase 1 at AACR 2026
CAMBRIDGE, Mass., April 17, 2026 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapies for oncology and inflammation and immunology (I&I), today announced multiple presentations that
More news about: Marengo Therapeutics
Apr 17, 2026, 08:22 ET IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
[email protected] 844-916-0895ImmunityBio, Inc. (IBRX) Securities Class Action: ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system
More news about: Hagens Berman Sobol Shapiro LLP
Apr 17, 2026, 08:00 ET Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
CARLSBAD, Calif., April 17, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
Apr 17, 2026, 06:00 ET Harbinger Health Presents Multiple Studies at AACR Reinforcing Platform Foundation for RESOLVE™, a New Category for Cancer Detection
Harbinger Health, a biotechnology company pioneering cancer resolution, today announced the presentation of multiple posters on Harbinger's platform and approach at the American
More news about: Harbinger Health
Apr 16, 2026, 15:57 ET Okuma America Corporation Receives Awards for Training Program at Rowan-Cabarrus Community College
than 30 areas of study, including arts and sciences, business, information technology, health and public services, engineering technologies, and biotechnology, as well as dozens of diplomas and certifications. Rowan-Cabarrus provides more than 2,000 course offerings, serving a yearly overall enrollment
More news about: Okuma America Corporation
Apr 16, 2026, 11:33 ET EVERGLADE HELPS LANDMARK BIO SECURE UP TO $18.3 MILLION IN ARPA-H FUNDING
Operating from its facility in Watertown, Massachusetts, the company combines process development, advanced analytics, and GMP manufacturing to help biotechnology and pharmaceutical partners translate breakthrough science into clinical and commercial reality. Learn more at
More news about: EverGlade Consulting
Apr 16, 2026, 10:00 ET Lilly confirms date and conference call for first-quarter 2026 financial results announcement
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Apr 16, 2026, 09:05 ET INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
[email protected] ALLEGATIONS: ImmunityBio is a biotechnology company that focuses on innovating, developing, and commercializing next-generation immunotherapies. According to the complaint, ImmunityBio's
More news about: Robbins Geller Rudman & Dowd LLP
Apr 16, 2026, 08:59 ET Quintara Biosciences Introduces AmpValue: $4.99 Full-Length Nanopore Amplicon Sequencing
AmpValue delivers full-length reads at a flat price of $4.99 per sample, coupled with guaranteed overnight turnaround to meet the rapid pace of modern biotechnology research. Unlike traditional transposase-based methods that mandate random fragmentation and result in terminal sequence loss, AmpValue employs
More news about: Quintara Biosciences
Apr 16, 2026, 08:36 ET STEMup Science and Technology Institute™ and ScienceWerx™ Form National Partnership to Advance Defense-Aligned Workforce Development and Technology Commercialization
clear pathways for military personnel, veterans, federal employees, and emerging professionals to transition into commercial innovation roles in biotechnology, AI, and advanced manufacturing.Leadership Perspectives"This partnership strengthens not only our technical base but our national
More news about: STEMup Science and Technology Institute